Triple-Negative Breast Cancers: Systematic Review of the Literature on Molecular and Clinical Features with a Focus on Treatment with Innovative Drugs
- 20 August 2018
- journal article
- review article
- Published by Springer Science and Business Media LLC in Current Oncology Reports
- Vol. 20 (10), 76
- https://doi.org/10.1007/s11912-018-0726-6
Abstract
Triple-negative breast cancer (TNBC) accounts for 15–20% of diagnosed breast tumours, with higher incidence in young and African-American women, and it is frequently associated with BRCA germline mutations. Chemotherapy is the only well-established therapeutic option in both early- and advanced-stages of the disease. TNBC tumours relapse earlier after standard anthracycline- and/or taxane-based chemotherapy treatments, generally within 1–3 years after the diagnosis, and often develop visceral metastases, representing the subtype with a worse prognosis among all breast cancers. In the present review, we will provide an updated overview of the available results of recent clinical trials for this disease and we will describe the implications of the known molecular pathways representing novel targets for development of future therapies for TNBC patients.Keywords
This publication has 56 references indexed in Scilit:
- Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patientsBMC Cancer, 2016
- Global Cancer Incidence and Mortality Rates and Trends—An UpdateCancer Epidemiology, Biomarkers & Prevention, 2016
- Identification and use of biomarkers in treatment strategies for triple‐negative breast cancer subtypesThe Journal of Pathology, 2013
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapiesJCI Insight, 2011
- Triple-Negative Breast CancerThe New England Journal of Medicine, 2010
- Response to taxanes in triple negative breast cancerCancer Chemotherapy and Pharmacology, 2008
- Triple-Negative Breast Cancer: Clinical Features and Patterns of RecurrenceClinical Cancer Research, 2007
- Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast CancerJNCI Journal of the National Cancer Institute, 2003
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences of the United States of America, 2001
- Molecular portraits of human breast tumoursNature, 2000